Biogen Inc.
NASDAQ:BIIBDrug Manufacturers - General
-$2.21 today
- Market cap
- $37.16B
- Beta
- 0.18
- P/E (TTM)
- 21.1
- EPS (TTM)
- $9.32
Volume 1.14M
Average 1.17M
BIIB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Biogen Inc.NASDAQ: BIIB
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $236.1M rose 21.5% year over year, ahead of the +13.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 15.5% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.
Context
- Depreciation & amortization amounted to 7.9% of revenue in FY2025, up 1.0 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +21.5% holds above the trailing-twelve-month pace of +13.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 779.9M USD
- Year-over-year change
- +15.8%
- 4-year CAGR
- +12.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 779.9M | +15.8% |
| FY2024 | 2024-12-31 | 673.2M | +36.1% |
| FY2023 | 2023-12-31 | 494.8M | -4.6% |
| FY2022 | 2022-12-31 | 518.4M | +6.3% |
| FY2021 | 2021-12-31 | 487.7M | — |
Depreciation & Amortization vs competitors
How BIIB compares with its peers on the latest reported figures
- BIIB's LTM Jun 2026 depreciation & amortization of $842.9M is the 5th largest of the 11 companies compared; the peer median is $375.35M.
- Its year-over-year change of +13.2% is the 5th highest of 11, against a peer median of +11.0%.
- Depreciation & amortization amounts to 8.5% of revenue for BIIB, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.58B | -3.0% | +9.2% | 10.3% | |
| LTM Sep 2026 | $6.41B | +29.8% | +3.0% | 10.3% | |
| LTM Jun 2026 | $4.67B | -15.5% | +14.8% | 12.2% | |
| LTM Jun 2026 | $2.1B | +10.9% | +9.5% | 2.6% | |
| LTM Jun 2026 | $842.9M | +13.2% | +14.6% | 8.5% | |
| LTM Jun 2026 | $528.6M | +3.6% | +16.8% | 3.4% | |
| LTM Jun 2026 | $222.1M | +11.2% | +12.3% | 1.8% | |
| LTM Jun 2026 | $91.5M | +14.8% | +18.6% | 2.9% | |
| LTM Jun 2026 | $55.3M | +97.1% | -33.0% | 5.5% | |
| LTM Jun 2026 | $54.76M | -3.1% | +7.8% | 1.1% | |
| LTM Sep 2026 | $28.19M | +36.7% | +0.9% | 2.9% | |
| Peer median (excluding BIIB) | $375.35M | +11.0% | +9.3% | 3.2% | |
Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.73B | 2.96B | 1.16B | 1.63B | 1.29B |
| Depreciation & Amortization | 487.7M | 518.4M | 494.8M | 673.2M | 779.9M |
| Deferred Income Tax | (426.8M) | (168.6M) | (305.8M) | (158.1M) | 361.6M |
| Stock-Based Compensation | 238.6M | 254.1M | 264.2M | 291.2M | 290.8M |
| Change in Working Capital | (145.5M) | (890.3M) | (648.7M) | (155.2M) | (1.06B) |
| Accounts Receivables | 326M | (222.4M) | 56.7M | 194.2M | 42.1M |
| Inventory | (462.4M) | (320.2M) | (130.9M) | (273.8M) | (64.7M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (9.1M) | (347.7M) | (574.5M) | (75.6M) | (1.04B) |
| Other Non-Cash Items | 1.76B | (1.29B) | 581.2M | 592.2M | 537M |
| Operating Cash Flow | 3.64B | 1.38B | 1.55B | 2.88B | 2.2B |
| Capital Expenditures | (258.1M) | (240.3M) | (311.4M) | (359.8M) | (153.8M) |
| Acquisitions (Net) | 28.1M | 595M | (6.91B) | (1.07B) | 0 |
| Purchases of Investments | (3.81B) | (3.45B) | (5.14B) | 0 | (1.26B) |
| Sales of Investments | 3.5B | 4.66B | 8.29B | 551.5M | 79.7M |
| Other Investing Activities | 12.9M | 24.4M | (11.3M) | 83.9M | (38.7M) |
| Investing Cash Flow | (563.7M) | 1.59B | (4.09B) | (799.2M) | (1.37B) |
| Debt Repayment | (170M) | (1B) | 187.3M | (650M) | (16.9M) |
| Common Stock Issued | (700K) | (1.9M) | (44.3M) | (31.3M) | (10M) |
| Common Stock Repurchased | (1.8B) | (750M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (115.5M) | (5.6M) | (6M) | (2.2M) | (275M) |
| Financing Cash Flow | (2.09B) | (1.76B) | 137M | (683.5M) | (301.9M) |
| Effect of Forex Changes | (59.8M) | (55.7M) | 35.1M | (67.7M) | 101.9M |
| Net Change in Cash | 930.2M | 1.16B | (2.37B) | 1.33B | 633.5M |
| Free Cash Flow | 3.38B | 1.14B | 1.24B | 2.52B | 2.05B |
Biogen Inc.
NASDAQ:BIIB
Intrinsic Alpha fair value
Locked
Current Price
$251.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.